Clinical Trials Logo

Recurrent Cancer clinical trials

View clinical trials related to Recurrent Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06208657 Not yet recruiting - Childhood Cancer Clinical Trials

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

A companion platform trial to test novel targeted agents based on the patient's tumor profile.

NCT ID: NCT04889742 Not yet recruiting - Prostate Cancer Clinical Trials

Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors

HETERERO
Start date: May 10, 2024
Phase: Phase 2
Study type: Interventional

This study investiagates deep-regional or superficial hyperthermia to enhance radiotherapy or chemoradiation in patients that suffer recurrent disease after previous radiotherapy.

NCT ID: NCT04784221 Not yet recruiting - Recurrent Cancer Clinical Trials

Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse

NANOPRO
Start date: June 2024
Phase: Phase 2
Study type: Interventional

This is a prospective multicenter non-randomized phase II study: proton therapy with nanoparticles based on polysiloxane and gadolinium chelates injectable intravenously

NCT ID: NCT02410187 Not yet recruiting - Recurrent Cancer Clinical Trials

SBRT for Extra-cranial Oligorecurrent Tumor

Start date: March 2016
Phase: Phase 2
Study type: Interventional

Clinical experience has shown that metastasis can often be limited in number and location, and thus amenable to local treatment. The term oligometastasis describes an intermediate state of cancer spread between localized disease and widespread metastasis. The implication of such an intermediate state is that the disease can be cured by using metastasis-directed therapy. Historically, in some patients with oligometastases in the liver or lungs, surgical resection was often indicated, as abundant evidence suggested it could improve progression-free or overall survival. Recently, several studies have reported promising outcomes of >80% local control with Stereotactic Body Radiotherapy (SBRT) in patients with lung or liver oligometastases. Nonetheless, very few studies have focused on non-liver, non-lung extracranial oligometastatic lesions treated with SBRT, and such studies have limitations of a retrospective nature and small sample sizes.Because allmost studies are based on single-arm studies without appropriate controls, the level of evidence to support SBRT is weak. Randomized trials are therefore necessary to establish the utility of SBRT for oligometastatic disease. This study is designed as a randomized phase II study. Patients will be randomized between current standard treatment (Arm 1) versus standard treatment +SBRT (Arm 2) to all known disease.